Spread of a disease inside a body
POPULARITY
9 episodes with Metastasis
6 episodes with Metastasis
8 episodes with Metastasis
13 episodes with Metastasis
4 episodes with Metastasis
3 episodes with Metastasis
4 episodes with Metastasis
2 episodes with Metastasis
4 episodes with Metastasis
2 episodes with Metastasis
3 episodes with Metastasis
2 episodes with Metastasis
2 episodes with Metastasis
6 episodes with Metastasis
6 episodes with Metastasis
7 episodes with Metastasis
2 episodes with Metastasis
2 episodes with Metastasis
Danielle studies triple-negative breast cancer (TNBC), an aggressive breast cancer subtype associated with poor survival. Unlike other subtypes for which there are targeted therapies, treatment options for TNBC are limited. In order to better understand the biology underlying TNBC, she studies a family of proteins called calpains. For upcoming interviews check out the Grad Chat webpage on Queen’s University School of Graduate Studies & Postdoctoral Affairs website.
Like the seeds of a dandelion drift on the wind and land other places, cancer can spread under the right conditions. How does cancer spread and why does it happen? We tackle these questions in this episode in our series “Everything you always wanted to know about cancer, but didn't have anyone to ask.” https://bit.ly/440dQKoIn This Episode:3:44 - Road Trip: Missouri and Recipe for Gooey Butter Cake5:22 - What is Your Life's Resume? A Short Guide to a Happy Life8:10 - What Makes Cancer Spread? (Metastasize)11:33 - Why Does Metastasis Happen?13:58 - Where Does Cancer Tend to Spread To?16:02 - Discussion About Metastatic Cancer17:42 - Discussion - How Do You Find Cancer?23:26 - What's Left of Me: Poems of a Dead Soul24:12 - OutroSimply put, metastasis is when the cancer moves from the original organ to another part of the body. The goal of treating metastatic cancer is to control it by stopping or slowing its growth. Some people can live for years with metastatic cancer that is well-controlled. The treatment depends on the type of primary cancer, where it has spread, previous cancer treatments, and general health.Cancer researchers, at the most basic level, focus their energy on what makes cancer cells start in the first place and what makes it metastasize. We've been talking the last few weeks about the basic aspects of cancer and this week we are going to talk about cancer cells going rogue and moving through the body. This is called metastasis, or stage 4 cancer. #cancer #metastaticcancer #metastasis #stage4 #stageIV #stupidcancer #cancersucks #healtheducation #publichealth #everyonedies #everydayisagift #palliativecare #cancerresources #cancereducation Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org
Gábor Somlyai, PhD is a Hungarian molecular biologist and world expert in the role of deuterium in cancer. He has published seminal work looking at the effects of various concentrations of this heavy isotope of hydrogen on growth and metastasis. Gábor's company, HYD LLC. for Cancer Research and Drug Development, has been at the forefront of developing deuterium depletion protocols as a synergistic cancer therapy. Their work over the last 30+ years has demonstrated the profound potential of deuterium depletion in not only cancer, but other disorders including type 2 diabetes. The identification of this submolecular regulatory system shaped by the relative abundance of deuterium to hydrogen in the body provides a framework with which we can further understand what cancer is and how sensitive our bodies are to subtle environmental information.All elements on the periodic table have isotopes - slightly different configurations of the same atoms that have slightly different chemical characteristics. Hydrogen is the simplest atom, with one proton, and one electron. But hydrogen also has another stable isotope called deuterium, with one proton, one electron and one neutron. This is still hydrogen, but it is double the atomic weight and consequently behaves differently. In our bodies, approximately 1 out of every 6600 hydrogen atoms (also referred to as 150ppm) is a deuterium atom. Our cells are exquisitely tuned to this deuterium/hydrogen ratio, and they use this ratio as a foundational signal in cell division. As deuterium levels shift, large scale changes in bioenergetics and genetic expression result. Gábor's work shows that lowering the deuterium level can effectively inhibit the growth of cancer cells.Gábor's WorkBook: Defeating Cancer: A New Way In Curing Cancer & Preserving HealthPreprintPreventa Deuterium Depleted WaterPublicationsHYD LLC. for Cancer Research and Drug DevelopmentFollow MeWebsiteSubstackConsultationInstagramYoutubeTwitter/XSpotifyAppleLinktree
Send us a textShort Summary: The science of cancer and immunity with Dr. Roychoudhuri, blending cutting-edge research with everyday implications like aspirin's role in fighting tumor metastasis.About the guest: Rahul Roychoudhuri, PhD is a Professor of Cancer Immunology at the University of Cambridge. His research bridges basic science and clinical applications, focusing on immune responses to cancer development and spread.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: The immune system's role in detecting and fighting cancer, particularly how cancer cells evade immunity through selection pressures and microenvironment manipulation. They explore cancer initiation via mutations and inflammation, metastasis mechanics, and a surprising link between low-dose aspirin and reduced cancer spread, spotlighting new research on T cells and thromboxane. The discussion ties in dietary fats, aspirin's anti-inflammatory and anti-clotting effects, and the potential for new therapies to prevent metastasis.Key Takeaways:The immune system constantly surveils and eliminates early cancer cells, but surviving cancers evolve to dodge detection.Inflammation can both spark cancer growth and be exploited by tumors to suppress helpful immune responses.Cancer metastasis, responsible for ~90% of cancer deaths, involves cells breaking off, traveling, and adapting to new sites.New research shows aspirin may curb metastasis by lowering thromboxane, a lipid-derived blood clotting factor.Human data hints aspirin reduces metastasis risk in cancers like breast and colorectal, but trials are ongoing.Daily low-dose aspirin (75-100 mg) is used for heart health, yet its cancer benefits need more study. 600 mg per day has been observed to reduce metastasis rates in colon cancer patients, but chronic use of that dose carries some risk (ulcers, bleeding).*Not medical advice.Support the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts
Live from TTLC25: Brain Metastasis by IASLC
Michael Lizardo, MS, PhD, a staff scientist in the Poul Sorensen laboratory at BC Cancer Agency, joins us on OsteoBites to discuss how the pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis.Dr. Lizardo shares his lab's recent findings in Clinical Cancer Research on how targeting the dysregulated mRNA translation factor eukaryotic initiation factor 4A (EIF4A), via pharmacological inhibitors, prevents the protein synthesis of nuclear factor erythroid 2–related factor 2 (NRF2), which is a cytoprotective protein metastatic OS cells require to successfully colonize the harsh microenvironment of the lung. He also discusses how the EIF4A1 inhibitor, CR-1-31B, and a related clinical-grade compound (Zotatifin) prevent OS cell adaptation to oxidative stress (a major stressor in the lung) in 2D and 3D cell culture models, as well as ex vivo lung organotypic cultures. Moreover, he discusses how drug treatment can inhibit lung metastasis and prolong the survival of animal subjects in pre-clinical mouse models of metastatic OS.
Blocking the Cancer Metastasis Enzyme MMP-9 with Beans and Chickpeas A type of saturated fat concentrated in meat and dairy seems to cause cancer to metastasize. Check out today's episode to find out more. Written by Dr. Michael Greger at @NutritionFacts.org #vegan #plantbased #plantbasedbriefing #cancer #saturatedfat #metastaticcancer #metastasis #mmp9 #wfpb #beans ============================ Original post: https://nutritionfacts.org/video/blocking-the-cancer-metastasis-enzyme-mmp-9-with-beans-and-chickpeas/ Related Episodes: 897: 95% of Americans Are Missing a Key Nutrient for Curbing Chronic Inflammation https://plantbasedbriefing.libsyn.com/897-95-of-americans-are-missing-a-key-nutrient-for-curbing-chronic-inflammation-by-dana-huedpohl-at-forksoverknivescom 373: [Part 1] Healing Autoimmune Disease With Supermarket Foods. https://plantbasedbriefing.libsyn.com/373-part-1-healing-autoimmune-disease-with-supermarket-foods-by-brooke-goldner-md-at-nutritionstudiesorg 374: [Part 2] Healing Autoimmune Disease With Supermarket Foods. https://plantbasedbriefing.libsyn.com/374-part-2-healing-autoimmune-disease-with-supermarket-foods-by-brooke-goldner-md-at-nutritionstudiesorg Also… use the search feature at https://www.plantbasedbriefing.com/episodes-search and search for INFLAMMATION ============================ Dr. Michael Greger is a physician, New York Times bestselling author, and internationally recognized speaker on nutrition, food safety, and public health issues. A founding member and Fellow of the American College of Lifestyle Medicine, Dr. Greger is licensed as a general practitioner specializing in clinical nutrition. He is a graduate of the Cornell University School of Agriculture and Tufts University School of Medicine. He founded NUTRITIONFACTS.ORG is a non-profit, non-commercial, science-based public service provided by Dr. Michael Greger, providing free updates on the latest in nutrition research via bite-sized videos. There are more than a thousand videos on nearly every aspect of healthy eating, with new videos and articles uploaded every day. His latest books —How Not to Age, How Not to Die, the How Not to Die Cookbook, and How Not to Diet — became instant New York Times Best Sellers. His two latest books, How to Survive a Pandemic and the How Not to Diet Cookbook were released in 2020. 100% of all proceeds he has ever received from his books, DVDs, and speaking engagements have always and will always be donated to charity. ============================== FOLLOW THE SHOW ON: YouTube: https://www.youtube.com/@plantbasedbriefing Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing LinkedIn: https://www.linkedin.com/company/plant-based-briefing/ Instagram: https://www.instagram.com/plantbasedbriefing/
What Causes Cancer to Metastasize and How to Potentially Help Control it with Diet A type of saturated fat concentrated in meat and dairy seems to cause cancer to metastasize. Check out today's episode to find out more. Written by Dr. Michael Greger at @NutritionFacts.org #vegan #plantbased #plantbasedbriefing #cancer #saturatedfat #metastaticcancer #metastasis #cd36 ============================ Original post: https://nutritionfacts.org/video/friday-favorites-what-causes-cancer-to-metastasize-and-how-to-potentially-help-control-it-with-diet Related Episodes: Use search feature at https://www.plantbasedbriefing.com/episodes-search Search for CANCER ============================ Dr. Michael Greger is a physician, New York Times bestselling author, and internationally recognized speaker on nutrition, food safety, and public health issues. A founding member and Fellow of the American College of Lifestyle Medicine, Dr. Greger is licensed as a general practitioner specializing in clinical nutrition. He is a graduate of the Cornell University School of Agriculture and Tufts University School of Medicine. He founded NUTRITIONFACTS.ORG is a non-profit, non-commercial, science-based public service provided by Dr. Michael Greger, providing free updates on the latest in nutrition research via bite-sized videos. There are more than a thousand videos on nearly every aspect of healthy eating, with new videos and articles uploaded every day. His latest books —How Not to Age, How Not to Die, the How Not to Die Cookbook, and How Not to Diet — became instant New York Times Best Sellers. His two latest books, How to Survive a Pandemic and the How Not to Diet Cookbook were released in 2020. 100% of all proceeds he has ever received from his books, DVDs, and speaking engagements have always and will always be donated to charity. ============================== FOLLOW THE SHOW ON: YouTube: https://www.youtube.com/@plantbasedbriefing Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing LinkedIn: https://www.linkedin.com/company/plant-based-briefing/ Instagram: https://www.instagram.com/plantbasedbriefing/
Send us a text27 minutes of hour and half Ep. RHOBH Teddi Mellencamp's cancer is terrifying. Kyle Richard's is a wreck. We go through the shocking timeline together to learn from it. I apologize. We move on to ALL the receipts related to the RHOP Karen Huger's alleged mystery man that jumped out of her car during her DUI. We get loads of clues but as always the devil is in the detail. We conclude that Karen's issues are way worst then people think. This gets us ready for RHOP S9 reunion P1 tonight. I remind you of the Sam Asghari gossip that he had a girl friend the whole time he was with Britney Spears and I think he just told us who she is. I take you through the clues. I do the ultimate DOGE deep dive using my expansive knowledge of political science, tech industry, all the gossip related to Elon and Altman. We discuss why academics call tech tycoons oligarchs, their secret vocabulary and all the pros and cons with them. I tell you about the secret inner working of DOGE Kids and what the policies their following are. I spill some openly guarded secrets about Tesla transparency. You will love this episode whether you are a Republican or Democrat and Pro Elon or not. I also break down all the debates in a simple and entertaining way.To join the Patreon and support my channel and join our fun conversations for $6 per month go here.https://www.patreon.com/DishingDramaWithDanaWilkeySupport the showDana is on Cameo!Follow Dana: @Wilkey_Dana$25,000 Song - Apple Music$25,000 Song - SpotifyTo support the show and listen to full episodes, become a member on PatreonTo learn more about sponsorships, email DDDWpodcast@gmail.comDana's YouTube Channel
Buildings and human designs for them are a remarkable expression of creativity and also share a remarkable creative space with music and literature. In this week's episode, Maurice and Chris explore Xeankis' Metastasis, the writings of Kepler, Solomon's Temple and Chris takes a hatchet to Ed Sheeran's 'Castle on the Hill'. This is all acheived while engaging in some very impressive parkour. First recorded 23rd of January 2025.
Among patients with colorectal cancer and synchronous liver metastases, the subgroup with a primary cancer in the rectum is especially challenging. Compared with colon cancer, most patients with stage IV rectal cancer will have locally advanced primary tumors at increased risk for obstructive and/or post-operative complications resulting in delays in systemic therapy. In this episode from the HPB team at Behind the Knife, listen in on the discussion about treatment sequencing for synchronous liver metastasis from rectal cancer Hosts Anish J. Jain MD (@anishjayjain) is a current PGY3 General Surgery Resident at Stanford University and a former T32 Research Fellow at the University of Texas MD Anderson Cancer Center. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center. Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center. Learning Objectives · Develop an understanding of the three treatment sequences for resection of disease in patients with synchronous liver metastasis from a primary rectal cancer (reverse, combined, and classic approach) · Develop an understanding of the benefits, risks, and nuances of each of the three treatment sequences · Develop an understanding of which patient cases each treatment sequence is ideal for as well as which cases they are not suitable for. Papers Referenced (in the order they were mentioned in the episode): 1) Conrad C, Vauthey JN, Masayuki O, et al. Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases. Ann Surg Oncol. 2017 Dec;24(13):3857-3864. https://pubmed.ncbi.nlm.nih.gov/28929463/ 2) Maki H, Ayabe RI, Nishioka Y, et al. Hepatectomy Before Primary Tumor Resection as Preferred Approach for Synchronous Liver Metastases from Rectal Cancer. Ann Surg Oncol. 2023 Sep;30(9):5390-5400. doi: 10.1245/s10434-023-13656-4. Epub 2023 Jun 7. Erratum in: Ann Surg Oncol. 2023 Sep;30(9):5405. https://pubmed.ncbi.nlm.nih.gov/37285096/ Additional Suggested Reading Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006 Jul;93(7):872-8. https://pubmed.ncbi.nlm.nih.gov/16671066/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
Study: The impact of exercise on dementiaNicotinamide Riboside - does it increase cancer risk and metastasis?
Poseedor de un lenguaje propio de Xenakis que conecta arquitectura y música a nivel estructural propone, con la música estocástica, la utilización de estructuras matemáticas en la praxis compositiva. Desarrolla el sistema UPIC y es pionero en el uso del algoritmo en la composición musical.____Has escuchadoLa Légende d'Eer. Nuevo remix en estéreo, a partir de la cinta original de siete canales, realizada del 3 al 4 de junio de 2004 por Gerard Pape. Mode (2005)Metastaseis (1953-1954). SWF Symphony Orchestra; Hans Rosbaud, director. Col Legno (2000)Oresteïa. Les Euménides (1965-1966, rev. 1989). L'Ensemble de Basse-Normandie; Dominique Debart, director; Ensemble Vocal d'Anjou; Robert Weddle, director de coros. Salabert Actuels (1990)Pléïades. Métaux (1978). Les Pléiades; Sylvio Gualda, director. Erato (1992)____Selección bibliográficaBARTHEL-CALVET, Anne-Sylvie, “MÉTASTASSIS-Analyse: un texte inédit de Iannis Xenakis sur Metastasis”. Revue de Musicologie, vol. 89, n.º 1 (2003), pp. 129-187*CASTANET, Pierre Albert, “We Must Open Our Ears and Eyes”: A Philosophical Lesson from the Polymath Iannis Xenakis”. Itamar. Revista de investigación musical: territorios para el arte, n.º 9 (2023), pp. 95-106DI SCIPIO, Agostino, “Compositional Models in Xenakis's Electroacoustic Music”. Perspectives of New Music, vol. 36, n.º 2 (1998), pp. 201-243*GIBSON, Benoît, The Instrumental Music of Iannis Xenakis: Theory, Practice, Self-Borrowing. Pendragon Press, 2011HARLEY, James, “The String Quartets of Iannis Xenakis”. Tempo, n.º 203 (1998), pp. 2-10*—, Xenakis. His Life in Music. Routledge, 2004HARLEY, Maria Anna, “Music of Sound and Light: Xenakis's Polytopes”. Leonardo, vol. 31, n.º 1 (1998), pp. 55-65*HILL, Peter, “Xenakis and the Performer”. Tempo, n.º 112 (1975), pp. 17-22*JONES, Evan, “Residue-Class Sets in the Music of Iannis Xenakis: An Analytical Algorithm and a General Intervallic Expression”. Perspectives of New Music, vol. 39, n.º 2 (2001), pp. 229-261*KANACH, Sharon, “Xenakis's Hand, or The Visualization of the Creative Process”. Perspectives of New Music, vol. 40, n.º 1 (2002), pp. 190-197*KANACH, Sharon (ed.), Performing Xenakis. Pendragon Press, 2010KIOURTSOGLOU, Elisavet, “An Architect Draws Sound and Light: New Perspectives on Iannis Xenakis's Diatope and La Légende d'Eer (1978)”. Computer Music Journal, vol. 41, n.º 4 (2017), pp. 8-31*LIZ, Ángel, “La alianza artes/ciencias a través de la obra de Iannis Xenakis”. Quodlibet: Revista de Especialización Musical, n.º 39 (2007), pp. 98-114*LUQUE, Sergio, “The Stochastic Synthesis of Iannis Xenakis”. Leonardo Music Journal, vol. 19 (2009), pp. 77-84*MÂCHE, François-Bernard, Portrait(s) de Iannis Xenakis. Bibliothèque Nationale de France, 2002MARCO ARAGÓN, Tomás, “Xenakis o la implacabilidad de la idea”. En: Jesús Villa Rojo (coord.), Músicas actuales: ideas básicas para una teoría. Ikeder, 2008*NAKIPBEKOVA, Alfia (ed.), Exploring Xenakis: Performance, Practice, Philosophy. Vernon Press, 2019PAPE, Gérard, Iannis Xenakis and the Ethics of Absolute Originality. UTEURP, 2023PARDO, Salgado, “El sonido cinemático. Iannis Xenakis”. En: Begoña López Herranz (coord.), Campos interdisciplinares de la musicología: V Congreso de la Sociedad Española de Musicología (Barcelona, 25-28 de octubre de 2000). Sociedad Española de Musicología, 2002*PECK, Robert W., “Toward an Interpretation of Xenakis's Nomos Alpha”. Perspectives of New Music, vol. 41, n.º 1 (2003), pp. 66-118*REYNOLDS, Roger, “Xenakis:… Tireless Renewal at Every Instant, at Every Death…”. Perspectives of New Music, vol. 41, n.º 1 (2003), pp. 4-64*REYNOLDS, Roger y Karen Reynolds, Xenakis Creates in Architecture and Music: The Reynolds Desert House. Routledge, 2022SERRA, Marie-Hélène, “Stochastic Composition and Stochastic Timbre: GENDY3 by Iannis Xenakis”. Perspectives of New Music, vol. 31, n.º 1 (1993), pp. 236-257*SOLOMOS, Makis, Iannis Xenakis. P. O. Éditions, 1996—, “El universo de la sonoridad en Xenakis”. Quodlibet: Revista de Especialización Musical, n.º 10 (1998), pp. 3-18*—, “The Unity of Xenakis's Instrumental and Electroacoustic Music: The Case for ‘Brownian Movements'”. Perspectives of New Music, vol. 39, n.º 1 (2001), pp. 244-254*—, “De l'apollinien et du dionysiaque dans les écrits de Xenakis”. En: Formel, informel: musique-philosophie. Editado por Makis Solomos, Antonia Soulez y Horacio Vaggione. L'Harmattan, 2003SOLOMOS, Makis (ed.), Iannis Xenakis: la musique électroacoustique. L'Harmattan, 2015SOUSTER, Tim, “Xenakis's Nuits”. Tempo, n.º 85 (1968), pp. 5-18*STERKEN, Sven, “Towards a Space-Time Art: Iannis Xenakis's Polytopes”. Perspectives of New Music, vol. 39, n.º 2 (2001), pp. 262-273*VARGA, Bálint A., Conversations with Iannis Xenakis. Faber and Faber, 1996XENAKIS, Iannis, Formalized Music: Thought and Mathematics in Composition. Pendragon Press, 1992—, Música de la arquitectura. Akal, 2009*XENAKIS, Iannis et al., “Xenakis on Xenakis”. Perspectives of New Music, vol. 25, n.º 1-2 (1987), pp. 16-63*XENAKIS, Iannis y Bálint András Varga, Conversations with Iannis Xenakis. Faber and Faber, 1996 *Documento disponible para su consulta en la Sala de Nuevas Músicas de la Biblioteca y Centro de Apoyo a la Investigación de la Fundación Juan March
In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests preview the publication of the Ninth Edition of Tumor, Node and Metastasis (TNM) Classification System for lung cancer. The new edition will be published in January 2025 and has some important changes that reflect an evolving understanding of the disease and more rigorous analysis of data from around the world. Guest: Dr. Valerie Rusch is a Thoracic Surgeon from Memorial Sloan Kettering Cancer CenterMSKCC where she is Vice Chair for Clinical Research in the Department of Surgery and the Miner Family Chair in Intrathoracic Cancers. She has held many leadership positions in the American College of Surgeons and other organizations and was part of the team to first described EGFR mutations. She has been chair of the Thoracic Committee for the American Joint Committee on Cancer 6th, 7th, 8th, and now 9th Editions of the Cancer Staging Handbook Guest: Dr. Hisao Asamura is a Professor of Surgery, Chief of Division of Thoracic Surgery at Keio University School of Medicine in Tokyo, Japan and Vice President of the Japan Lung Cancer Society. For IASLC, he is the Chair of the Staging and Prognostic Factors Committee, former Executive Board Director, and Congress President for the 18th World Conference on Lung Cancer. Guest: Dr. Enrico Ruffini is a Thoracic Surgeon and Professor of Thoracic Surgery from the University of Torino, Italy where he is the Chief of the Thoracic Surgery Unit and Director of the Thoracic Surgery Residency Program. He is heavily involved in the European Society of Thoracic Surgeons and Chair of the IASLC Staging and Prognostic Factors Committee – Thymic domain.
The plant Cannabis sativa L. has historically served as a herbal remedy, garnering a considerable surge in both recreational and medicinal domains in contemporary times. However, this increased application has not aligned with our clinical awareness regarding the disturbances associated with cannabis. This assumes heightened significance in the context of palliative care for cancer patients, as the parameters controlling the interactions between cannabis and cancer have remained poorly defined. For upcoming interviews check out the Grad Chat webpage on Queen’s University School of Graduate Studies & Postdoctoral Affairs website.
Send us a textIn this episode of DigiPath Digest, we review the latest AI developments in digital pathology described in the literature. I explore how AI is pushing the boundaries of metastasis detection, breast cancer treatment predictions, lung cancer research trends, and the creation of pathology foundation models. Episode Breakdown:00:00 – Welcome & Introduction00:36 – Sentinel Node Metastasis Detection: A discussion on the development of an AI model that can detect sentinel node metastasis in melanoma with accuracy comparable to that of pathologists. The model aids in distinguishing between nodal metastasis and intra-nodal nevus, which is crucial for accurate staging in melanoma patients.05:01 – Predicting Breast Cancer Treatment Response: A cross-modal AI model that integrates pathology images and ultrasound data is explored. This model is designed to predict a breast cancer patient's response to neoadjuvant chemotherapy, providing personalized insights that can guide treatment decisions.09:59 – Global Trends in AI and Lung Cancer Pathology: This section reviews a bibliometric study that analyzed global research trends in AI-based digital pathology for lung cancer over the past two decades. The study highlights the need for increased collaboration between institutions and countries to further AI advancements in this area.13:30 – Pathology Foundation Models: An in-depth look at a new foundation model in pathology, designed to generalize across various diagnostic tasks. This model shows significant promise in cancer diagnosis and prognosis prediction, outperforming traditional deep learning methods by addressing domain shifts across different datasets.20:08 – Domain Shifts in AI Models: A brief discussion on the impact of domain shifts, such as variations in staining protocols and patient populations, on the performance of AI models in pathology. Strategies for mitigating these challenges are highlighted.29:09 – Faster Annotation in Pathology: The episode concludes with a review of a study comparing manual and semi-automated annotation methods. The semi-automated approach significantly reduces the time required for annotating whole slide images, offering a more efficient solution for pathologists.Resources Mentioned:
DermSurgery Digest at the Microscope dives deep into the latest dermatology literature exploring the latest techniques and diagnosis approaches. Each quarterly episode features interesting and relevant articles from Dermatologic Surgery, American Journal of Dermatopathology, Journal of Cutaneous Pathology, American Journal of Surgical Pathology and more. This episode features articles on cutaneous and subcutaneous leiomyosarcoma.Contributors to this podcast include Naomi Lawrence, MD, Dermatologic Surgery Digital Content Editor; Ashley Elsensohn, MD, MPH, DermSurgery Digest At the Microscope co-host; Christine Ahn, MD; Jeff Gardner, MD; Marina K. Ibraheim, MD; and Michael P. Lee, MD.Articles featured include:Kraft S, Fletcher CD. Atypical intradermal smooth muscle neoplasms: clinicopathologic analysis of 84 cases and a reappraisal of cutaneous "leiomyosarcoma". Am J Surg Pathol. 2011 Apr;35(4):599-607. doi: 10.1097/PAS.0b013e31820e6093. PMID: 21358302.Kazlouskaya V, Lai YC, Khachemoune A. Leiomyosarcoma of the skin: review of the literature with an emphasis on prognosis and management. Int J Dermatol. 2020 Feb;59(2):165-172. doi: 10.1111/ijd.14705. Epub 2019 Nov 14. PMID: 31729020.Winchester DS, Hocker TL, Brewer JD, Baum CL, Hochwalt PC, Arpey CJ, Otley CC, Roenigk RK. Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. J Am Acad Dermatol. 2014 Nov;71(5):919-25. doi: 10.1016/j.jaad.2014.07.020. Epub 2014 Aug 29. PMID: 25174541.Bresler SC, Gosnell HL, Ko JS, Angeles CV, Ronen S, Billings SD, Patel RM. Subcutaneous Leiomyosarcoma: An Aggressive Malignancy Portending a Significant Risk of Metastasis and Death. Am J Surg Pathol. 2023 Dec 1;47(12):1417-1424. doi: 10.1097/PAS.0000000000002126. Epub 2023 Sep 19. PMID: 37727934.Listeners are encouraged to submit questions for podcast hosts to answer in a later episode. To submit your questions, email communicationstaff@asds.net.
BUFFALO, NY- August 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.” The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular compartments as well as to transport protons across the plasma membrane of various cell types, including cancer cells. Researchers Zhen Li, Mohammed A. Alshagawi, Rebecca A. Oot, Mariam K. Alamoudi, Kevin Su, Wenhui Li, Michael P. Collins, Stephan Wilkens, and Michael Forgac from Tufts University School of Medicine; Tufts University; Dana Farber Cancer Institute, Harvard Medical School; University of Minnesota School of Medicine; Prince Sattam Bin Abdulaziz University; Korro Bio; SUNY Upstate Medical University; and Foghorn Therapeutics, have previously shown that selective inhibition of plasma membrane V-ATPases in breast tumor cells inhibits the invasion of these cells in vitro. They have now developed a nanobody directed against an extracellular epitope of the mouse V-ATPase c subunit. “We show that treatment of 4T1-12B mouse breast cancer cells with this nanobody inhibits V-ATPase-dependent acidification of the media and invasion of these cells in vitro.” The research team further found that injecting this nanobody into mice implanted with 4T1-12B cells orthotopically in the mammary fat pad inhibited the metastasis of tumor cells to the lungs. “In conclusion, our results indicate that a nanobody directed against an extracellular epitope expressed on the surface of the V-ATPase is able to inhibit activity of cell surface V-ATPases in 4T1-12B breast cancer cells, inhibit in vitro invasion of these cells and inhibit metastasis of these cells to lung following their implantation in the mammary fat pad of mice.” DOI - https://doi.org/10.18632/oncotarget.28638 Correspondence to - Michael Forgac - michael.forgac@tufts.edu Video short - https://www.youtube.com/watch?v=4eLGqvSfAgg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28638 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, vacuolar ATPase, breast cancer, invasion, tumor metastasis, tumor growth About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Show notes and links: https://www.chrisbeatcancer.com/dr-christine-salter-on-healing-cancer-with-integrative-therapies/
In this episode of The Back Table MSK Podcast, Dr. Alexa Levey discusses the importance of multidisciplinary treatment planning for sarcomas with Dr. Yvette Ho and Dr. Jessica Jones. --- CHECK OUT OUR SPONSOR Stryker Interventional Spine https://www.strykerivs.com --- SYNPOSIS The conversation explores the necessity of a multidisciplinary approach and the challenges associated with managing both osseous and soft tissue sarcomas. Dr. Jones highlights recent advancements in precision medicine, including a novel drug, nirogacesta, for desmoid tumors. Dr. Ho addresses common misconceptions surrounding desmoid tumors, emphasizing their potential for significant tissue destruction, and shares insights from her experience in limb salvage surgery. Dr. Levey discusses the considerations involved in needle biopsy and presents case studies where cryoablation effectively reduced desmoid tumor sizes. The doctors also discuss strategies for managing nociceptive and mechanical pain, such as intrathecal pain pumps, radiation therapy, and kyphoplasty. --- TIMESTAMPS 00:00 - Introduction 03:51 - Challenges in Sarcoma Management 13:06 - Precision Medicine in Treatment Planning 16:44 - The Role of Biopsy 20:51 - The Importance of Specialized Oncology Care 25:13 - Collaboration Throughout Treatment Course 31:03 - Cryoablation and Case Studies 35:13 - New Drug Development for Desmoid Tumors 39:06 - Limb Salvage Considerations 41:13 - Metastasis, Recurrence, and Pain Management 49:57 - Final Thoughts --- RESOURCES OGSIVEO (Nirogacestat): https://www.ogsiveo.com/
Circulating tumor DNA, more commonly referred to as ctDNA, has emerged as an attractive and potentially highly sensitive biomarker for patients with colorectal cancer. But what exactly is ctDNA, does it have any prognostic value for patients with colorectal liver metastasis, and how can it be incorporated into the management of said patients? In this episode from the HPB team at Behind the Knife, listen in on the discussion about ctDNA and its role in the perioperative management of colorectal liver metastasis. Hosts Anish J. Jain MD (@anishjayjain) is a T32 Research Fellow at the University of Texas MD Anderson Cancer Center within the Department of Surgical Oncology. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center. Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center Learning Objectives: -Develop an understanding of what circulating tumor DNA (ctDNA) is. -Develop an understanding of what makes ctDNA unique from other “tumor markers” like CEA. -Develop an understanding of the prognostic value of ctDNA for colorectal liver metastasis (CRLM). -Develop an understanding of the current role of ctDNA in the perioperative treatment of patients with CRLM. -Develop an understanding of how ctDNA can be incorporated into future treatment algorithms for patients undergoing hepatic resection for CRLM. Papers Referenced (in the order they were mentioned in the episode): 1) Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023;277(5):813-820. https://pubmed.ncbi.nlm.nih.gov/35797554/ 2) Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022;234(4):474-483. https://pubmed.ncbi.nlm.nih.gov/35290266/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen
Janani S. Reisenauer, MD; Patrick W. Eiken, MD; and Dawn Owen, MD PhD, join journal CHEST Podcast Moderator Dominique Pepper, MD, to discuss new research comparing outcomes for metastasis-directed therapies including sublobar resection, stereotactic body radiation therapy, and percutaneous ablation.
In today's world, the sad reality is that we've become far more sedentary than previous generations, with most of our lives forced into desk jobs or innovations that encourage us to prioritize convenience over movement. In this episode, we're rewiring the way we think about movement - as a form of medicine against chronic disease. Meet Darryl Edwards, a movement coach and author who spent nearly two decades in the corporate world -- and realized something needed to change. Today, he is the founder of the Primal Play Method and a physical activity, health, and play researcher, specializing in combatting chronic lifestyle diseases that plague modern society. In 2019, Darryl's TEDxTalk, "Why working out isn't working out," garnered over a million views, exploring the root causes of physical inactivity and our inherent resistance to traditional exercise routines.In this episode, we talk about how modern sedentary lifestyles, with prolonged sitting and limited physical activity, are contributing significantly to the rise of chronic diseases. Darryl stresses that movement is not merely a form of exercise but a fundamental aspect of our health—a powerful medicine that can slash the risk of disease by up to 50%. We discuss the need for restructuring of daily routines to incorporate more active habits and natural movement throughout the day instead of relying entirely on 1-hour workout sessions. As a play researcher, Darryl believes that embracing our inner child is the key to fostering a more positive and playful attitude towards active movement. He shares his everyday morning routine, showcasing practical ways to infuse movement into daily life beyond traditional exercise formats. Tune in for an engaging episode with Darryl Edwards as he champions the transformative potential of playful movement and its profound impact of movement on immune function, cancer prevention, and overall longevity.HIGHLIGHTS[1:15] Why Natural Movement Matters[2:35] Darryl's TED Talk on Our Love-Hate Relationship with Exercise[4:20] How Being Sedentary Leads to Chronic Disease[8:00] Modern Society Is Making Us Sedentary and Sick[14:50] Why Embracing the Inner Child Is Necessary[18:38] Darryl's Everyday Morning Routine[24:25] The Community Power of Crossfit[26:15] Why Our 1 Hour Workout Is Not Enough[31:05] How Movement Is Medicine[38:44] Aeorebic Exercise and Its Effect on the Metastasis of Cancer Cells[41:40] Improving Your Immunosenescence and Immunosurvelillance With MovementGUEST LINKSWebsite: https://www.primalplay.com/Instagram: https://www.instagram.com/fitnessexplorer/LinkedIn: https://www.linkedin.com/in/fitnessexplorer/Youtube: https://www.youtube.com/fitnessexplorerWhy Working Out Isn't Working Out TEDx Talk: https://youtu.be/NoN2b-b2c0o?si=CJO_PaUKjsTwjzWvAnimal Moves: How to move like an animal to get you leaner, fitter, stronger and healthier for life: https://a.co/d/aRgNuOM30-day Animal Moves Challenge: https://courses.primalplay.com/p/animal-moves-challenge UPGRADE YOUR WELLNESSMarion Institute BioMed Course: biologicalmedicine.orgCode: beautifullybrokenSilver Biotics Wound Healing Gel: https://bit.ly/3JnxyDDCode: BEAUTIFULLYBROKENLightPathLED https://lightpathled.com/?afmc=BEAUTIFULLYBROKENCode: beautifullybrokenSTEMREGEN: https://www.stemregen.co/products/stemregen/?afmc=beautifullybrokenCode: beautifullybrokenGOT MOLD?: https://www.gotmold.com/beautifullybroken/Code: beautifullybroken10Flowpresso 3-in-1 technology: https://www.beautifullybroken.world/flowpressoMedical grade Ozone Therapy: https://lddy.no/1djnhCode: BEAUTIFULLYBROKENAquaCure Machine + Molecular HydrogenWebsite:https://eagle-research.com?ref=24931Code: beautifullybrokenDIY Home Cold Exposure: https://www.penguinchillers.com/product/beautifullybroken/My Favorite Sauna: Therasage https://bit.ly/39mTxwYCode: BEAUTIFULLYBROKENCONNECT WITH FREDDIECheck out my website and store:www.beautifullybroken.worldInstagram – https://www.instagram.com/beautifullybroken.world/YouTube: https://www.youtube.com/@BeautifullyBrokenWorld
Rachel Offenbacher, MD, is an attending physician at Children's Hospital at Montefiore (CHAM) and Assistant Professor, Pediatric Hematology, Oncology, Marrow and Blood Cell Transplantation at Montefiore Einstein. She joins us on OsteoBites to share her work on targeting urea cycle dysfunction to prevent and treat osteosarcoma metastasis.Since joining the Montefiore team, Dr. Offenbacher's clinical focus has been pediatric sarcomas. As a member of a translational sarcoma research lab, Dr. Offenbacher is fascinated by the ability to explore the biological processes behind novel therapeutic approaches before they are used in the clinic. Her research focuses on utilizing difluoromethylornithine to prevent and treat metastatic osteosarcoma. She has seen impressive results in her in vitro and in vivo models and is working to initiate a clinical trial. She is simultaneously working on a project funded by the American Association of Cancer Research, Targeting the Tumor Microenvironment of Metastasis to Treat Metastatic Ewing Sarcoma, which is demonstrating promising results. Dr. Offenbacher's work has been published in numerous peer-reviewed journals and presented nationally and internationally. Dr. Offenbacher is board certified in General Pediatrics by the American Board of Pediatrics. She is a member of several professional organizations, including the American Association for Cancer Research, the Children's Oncology Group and the American Society of Pediatric Hematology/Oncology. Dr. Offenbacher is also an active member of the National Pediatric Cancer Foundation. In 2020 and 2022, she won the Leo M. Davidoff Society Teaching Award; in 2022, she won the Pediatric Research Day Oral Presentation Award from CHAM. Dr. Offenbacher is a volunteer pediatric oncologist at Camp Simcha, a residential camp for children with cancer.
Cancer has a major impact on our society with approximately 1 in 3 adults in the U.S. diagnosed during their lifetimes. This program looks at the role of exercise and physical activity and their benefits for cancer patients. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 39647]
Cancer has a major impact on our society with approximately 1 in 3 adults in the U.S. diagnosed during their lifetimes. This program looks at the role of exercise and physical activity and their benefits for cancer patients. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 39647]
Cancer has a major impact on our society with approximately 1 in 3 adults in the U.S. diagnosed during their lifetimes. This program looks at the role of exercise and physical activity and their benefits for cancer patients. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 39647]
Cancer has a major impact on our society with approximately 1 in 3 adults in the U.S. diagnosed during their lifetimes. This program looks at the role of exercise and physical activity and their benefits for cancer patients. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 39647]
Cancer has a major impact on our society with approximately 1 in 3 adults in the U.S. diagnosed during their lifetimes. This program looks at the role of exercise and physical activity and their benefits for cancer patients. Series: "Mini Medical School for the Public" [Health and Medicine] [Show ID: 39647]
Learn all about stomach cancer treatment, symptom management, and end-stage disease.In Part 1 we talked about risk factors, symptoms, diagnosis, staging, and survival estimates. This week for Part 2 of our discussion we review treatment options, symptom management, end-stage disease, and how you can support someone with stomach cancer.In this Episode:00:00 – Our Sponsor: Tree of Life Memorials and Digital & Stone00:20 – Intro02:18 – How to Lower Your Risk for Stomach Cancer09:50 – Recipe of the Week: Popcorn Balls12:39 – Stomach Cancer Treatment21:01 – Stomach Cancer Symptom Management33:14 – End-Stage Stomach Cancer41:49 – How to Support Someone with Stomach Cancer50:24 – Greg's Journal: The Loneliness of Caring for Someone with Alzheimer's Disease54:00- OutroFollow us on Facebook | Instagram | Email us at mail@every1dies.orgClick on this link to Rate and Review our podcast!
As read by George Hahn. https://www.profgalloway.com/metastasis/ Learn more about your ad choices. Visit podcastchoices.com/adchoices
The Role of ‘Forever Chemicals' in Cancer Metastasis with guest Dr. Caroline Johnson February 4, 2024
Surgical resection of bilateral colorectal liver metastasis (CLM) can pose a significant challenge to even the most experienced HPB surgeon. Is surgical resection justified, if so, in which patients? What's the best surgical approach for curative intent resection of all lesions, and does ablation play a role? In this episode from the HPB team at Behind the Knife, listen in on the discussion about the surgical management of patients with bilateral colorectal liver metastasis. Hosts Anish J. Jain MD (@anishjayjain) is a T32 Research Fellow at the University of Texas MD Anderson Cancer Center within the Department of Surgical Oncology. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center. Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center Learning Objectives: · Develop an understanding of patient selection for surgical resection of bilateral colorectal liver metastasis (CLM). · Develop an understanding of the use of Two Stage Hepatectomy (TSH) versus Parenchymal Sparing Hepatectomy (PSH) in the treatment of bilateral CLM. · Develop an understanding of if and when to use ablative procedures for resection of bilateral CLM. · Develop an understanding of selection and management of patients who suffer recurrence after resection of bilateral CLM. Suggested Readings · Omichi K, Shindoh J, Cloyd JM, Mizuno T, Chun YS, Conrad C, Aloia TA, Tzeng CD, Vauthey JN. Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis. Eur J Surg Oncol. 2018 Jan;44(1):122-129. doi: 10.1016/j.ejso.2017.11.006. Epub 2017 Nov 24. PMID: 29208318; PMCID: PMC5742306. https://pubmed.ncbi.nlm.nih.gov/29208318/ · Kawaguchi Y, Kopetz S, Tran Cao HS, Panettieri E, De Bellis M, Nishioka Y, Hwang H, Wang X, Tzeng CD, Chun YS, Aloia TA, Hasegawa K, Guglielmi A, Giuliante F, Vauthey JN. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status. Br J Surg. 2021 Aug 19;108(8):968-975. doi: 10.1093/bjs/znab086. PMID: 33829254; PMCID: PMC8378514. https://pubmed.ncbi.nlm.nih.gov/33829254/ · Nishioka Y, Paez-Arango N, Boettcher FO, Kawaguchi Y, Newhook TE, Chun YS, Tzeng CD, Tran Cao HS, Lee JE, Vreeland TJ, Vauthey JN. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases. J Gastrointest Surg. 2022 Apr;26(4):791-801. doi: 10.1007/s11605-021-05173-0. Epub 2021 Nov 1. PMID: 34725784. https://pubmed.ncbi.nlm.nih.gov/34725784/ · Passot G, Chun YS, Kopetz SE, Zorzi D, Brudvik KW, Kim BJ, Conrad C, Aloia TA, Vauthey JN. Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases. J Am Coll Surg. 2016 Jul;223(1):99-108. doi: 10.1016/j.jamcollsurg.2015.12.057. Epub 2016 Jan 18. PMID: 26968325; PMCID: PMC4925205. https://pubmed.ncbi.nlm.nih.gov/26968325/ · Donadon M, Cescon M, Cucchetti A, Cimino M, Costa G, Pesi B, Ercolani G, Pinna AD, Torzilli G. Parenchymal-Sparing Surgery for the Surgical Treatment of Multiple Colorectal Liver Metastases Is a Safer Approach than Major Hepatectomy Not Impairing Patients' Prognosis: A Bi-Institutional Propensity Score-Matched Analysis. Dig Surg. 2018;35(4):342-349. doi: 10.1159/000479336. Epub 2017 Oct 14. PMID: 29032372. https://pubmed.ncbi.nlm.nih.gov/29032372/ · Lillemoe HA, Kawaguchi Y, Passot G, Karagkounis G, Simoneau E, You YN, Mehran RJ, Chun YS, Tzeng CD, Aloia TA, Vauthey JN. Surgical Resection for Recurrence After Two-Stage Hepatectomy for Colorectal Liver Metastases Is Feasible, Is Safe, and Improves Survival. J Gastrointest Surg. 2019 Jan;23(1):84-92. doi: 10.1007/s11605-018-3890-y. Epub 2018 Aug 6. PMID: 30084064; PMCID: PMC6329635. https://pubmed.ncbi.nlm.nih.gov/30084064/ · Panettieri E, Kim BJ, Kawaguchi Y, Ardito F, Mele C, De Rose AM, Vellone M, Chun YS, Tzeng CD, Aloia TA, Giuliante F, Vauthey JN. Survival by Number and Sites of Resections of Recurrence after First Curative Resection of Colorectal Liver Metastases. J Gastrointest Surg. 2022 Dec;26(12):2503-2511. doi: 10.1007/s11605-022-05456-0. Epub 2022 Sep 20. PMID: 36127553. https://pubmed.ncbi.nlm.nih.gov/36127553/ ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9*** Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our recent Hepatobiliary Surgery episodes here: https://app.behindtheknife.org/podcast-category/hepatobiliary
In this episode of the Family Pet Podcast, Dr. Katelyn Marlowe discusses veterinary oncology and the similarities and differences between human and pet cancers. She explains the causes of cancer and the various ways it can be diagnosed in pets. Dr. Marlowe also explores the different treatment options available, including surgery, chemotherapy, radiation therapy, and targeted therapies. She emphasizes the importance of considering the pet's quality of life when making treatment decisions. The episode concludes with a fun fact about contagious cancers in dogs and Tasmanian devils.TakeawaysCancer in pets is similar to cancer in humans, with some types of cancer being more common in certain species.Diagnosing cancer in pets often involves physical examinations, blood work, imaging tests, and biopsies.Treatment options for cancer in pets include surgery, chemotherapy, radiation therapy, and targeted therapies.The cost of cancer treatment for pets can vary depending on the type of cancer and the chosen treatment approach.It is important for pet owners to consider the pet's quality of life when making treatment decisions.Chapters00:00 Introduction02:24 Introduction to Veterinary Oncology04:20 Comparison of Human and Pet Cancers06:00 Common Cancers in Animals07:09 Understanding Cancer and its Effects08:44 Causes of Cancer09:00 Diagnosing Cancer in Pets13:10 Use of AI in Cancer Diagnosis15:50 Treatment Options for Cancer20:26 Quality of Life Considerations22:16 Financial Considerations25:08 Definitions: Benign, Malignant, Metastasis, Margins, Systemic, Remission30:47 Importance of Informed Decision-Making32:02 Fun Fact: Contagious Cancers34:35 Conclusion
Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, emphasizes the importance of the RAGE receptor in diseases like cancer and inflammation. Their lead compound, azeliragon, blocks the activation of the RAGE receptor and shows effectiveness in inhibiting cancer metastasis and enhancing the impact of radiation. Clinical trials are underway for breast cancer, pancreatic cancer, glioblastoma, and COVID-19. This approach addresses the cancer cells and the microenvironment in which they reside to reduce disease progression and alter the immune environment. Steve explains, "RAGE is a receptor on the surface of cells that sends signals to the cell that can either enhance or harm health. When over-activated, RAGE has been implicated in a wide range of inflammatory diseases and cancers. In cancer, in particular, over-activation of RAGE has been associated with both the invasiveness of cancer, with the progression of cancer, and with metastasis of cancer." "Azeliragon blocks the binding of anything that can activate RAGE. The molecules, the proteins that bind to RAGE, are collectively called ligands, ligands meaning something that ligates or binds to the receptor. What azeliragon does is it binds to the receptor. It binds to the portion of the receptor that accepts the ligands and, therefore, blocks the binding of all the ligands. So it's a little bit like if you imagine a lock and the key, and it's almost like putting gum inside the keyhole so the key won't fit in. It's the same type of thing whereby by binding to the receptor, none of the ligands can bind to it." "One of the attractive things about azeliragon is that it's a capsule. It's a pill taken by mouth. Originally the drug was developed for Alzheimer's disease, and we're repurposing it as a treatment of cancer. In those early clinical trials in Alzheimer's disease, it was remarkably safe. Patients had very little, if any, side effects from the drug. It was comparable to the placebo arm of the clinical trial. The drug is taken once a day by mouth. In the early clinical trials, it was taken for as long as 18 months every day. Another attractive thing about this is that the tumor will be exposed to the drug every day because the person is taking the drug every day." #Cantex #RAGE #RAGEReceptor #Azeliragon #PancreaticCancer #Glioblastoma #Cancer cantex.com Listen to the podcast here
Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, emphasizes the importance of the RAGE receptor in diseases like cancer and inflammation. Their lead compound, azeliragon, blocks the activation of the RAGE receptor and shows effectiveness in inhibiting cancer metastasis and enhancing the impact of radiation. Clinical trials are underway for breast cancer, pancreatic cancer, glioblastoma, and COVID-19. This approach addresses the cancer cells and the microenvironment in which they reside to reduce disease progression and alter the immune environment. Steve explains, "RAGE is a receptor on the surface of cells that sends signals to the cell that can either enhance or harm health. When over-activated, RAGE has been implicated in a wide range of inflammatory diseases and cancers. In cancer, in particular, over-activation of RAGE has been associated with both the invasiveness of cancer, with the progression of cancer, and with metastasis of cancer." "Azeliragon blocks the binding of anything that can activate RAGE. The molecules, the proteins that bind to RAGE, are collectively called ligands, ligands meaning something that ligates or binds to the receptor. What azeliragon does is it binds to the receptor. It binds to the portion of the receptor that accepts the ligands and, therefore, blocks the binding of all the ligands. So it's a little bit like if you imagine a lock and the key, and it's almost like putting gum inside the keyhole so the key won't fit in. It's the same type of thing whereby by binding to the receptor, none of the ligands can bind to it." "One of the attractive things about azeliragon is that it's a capsule. It's a pill taken by mouth. Originally the drug was developed for Alzheimer's disease, and we're repurposing it as a treatment of cancer. In those early clinical trials in Alzheimer's disease, it was remarkably safe. Patients had very little, if any, side effects from the drug. It was comparable to the placebo arm of the clinical trial. The drug is taken once a day by mouth. In the early clinical trials, it was taken for as long as 18 months every day. Another attractive thing about this is that the tumor will be exposed to the drug every day because the person is taking the drug every day." #Cantex #RAGE #RAGEReceptor #Azeliragon #PancreaticCancer #Glioblastoma #Cancer cantex.com Download the transcript here
Mitochondrial biogenesis, the process of increasing the size and number of mitochondria within cells, plays a crucial role in cancer metastasis. Metastasizing cells exhibit a unique metabolism that differs from the well-known Warburg effect observed in primary tumors. While primary tumors primarily rely on glycolysis for energy production, metastatic cells rely on oxidative phosphorylation and ATP generation for short-term energy needs. However, over longer time frames, mitochondrial biogenesis becomes a prominent feature in the success of metastasis. In a new study, researchers Gulimirerouzi Fnu and Georg F. Weber from the University of Cincinnati's James L. Winkle College of Pharmacy investigate the connection between short-term oxidative metabolism and long-term mitochondrial biogenesis in cancer metastasis. They hypothesized that Osteopontin splice variants, specifically Osteopontin-c, stimulate an increase in mitochondrial size through the activation of specific signaling mechanisms. On December 1, 2023, their new research paper was published in Oncotarget, entitled, “Osteopontin induces mitochondrial biogenesis in deadherent cancer cells.” Full blog - https://www.oncotarget.org/2024/01/11/how-osteopontin-stimulates-mitochondrial-mass-and-cancer-metastasis/ Paper DOI - https://doi.org/10.18632/oncotarget.28540 Correspondence to - Georg F. Weber - georg.weber@uc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28540 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, metastasis, metabolism, anchorage independence, mitochondrial mass, peroxide About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Why have we not found the cure for cancer yet? Neil deGrasse Tyson, Chuck Nice, and Gary O'Reilly explore paradigm shifts in cancer treatment, molecular biology, and a promising new cancer drug AOH1996 with City of Hope cancer researcher Dr. Linda Malkas. NOTE: StarTalk+ Patrons can listen to this entire episode commercial-free.Thanks to our Patrons Willie Bass, Nicholas A Jones, Edwin Goel, Joe Gibbs, Shane Alexander, Keith Goodman, and James Kuntz for supporting us this week.Photo Credit: Dr. Cecil Fox (Photographer), Public domain, via Wikimedia Commons
Diesmal mit Podcasts, Prozessoren, Eldenring, Fantasy Bücher mit Wendungen, berührende Filme, Breaking Bad beziehungsweise Metastasis, Alkohol im Job, und der Welt auf den Brettern die die Welt bedeuten. Im nächsten Jahr gibt es noch Live-Termine in Frankfurt und Berlin: 05.03.24 Frankfurt 08.03.24 Berlin Karten gibt es ab sofort bei [Eventim!](https://www.eventim.de/eventseries/bastian-bielendorfer-reinhard-remfort-alliteration-am-arsch-aaa-podcast-3447644/) Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/AlliterationAmArsch
BUFFALO, NY- October 18, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “The nuclear envelope and metastasis.” In their new editorial, researchers Emily Hansen and James M. Holaska from Rowan University discuss nuclear morphology — one of the basic visual criteria used by pathologists to diagnose breast cancer. Immunofluorescence staining of the nuclear structural proteins lamin B and emerin was recommended as an effective diagnostic tool for both thyroid and breast cancer, suggesting nuclear structure is intimately tied to malignant transformation. But what role nuclear morphology plays in cancer transformation and progression remains unclear. “The most likely explanation for why cancer cells present with distinct nuclear morphology is thought to be related to the most likely route of cancer spread: the vasculature.” For a tumor to metastasize, cancer cells need to enter and exit the blood and lymphatic vessels by squeezing through extremely small gaps in the endothelium, most of which are 1.2–2 µm in diameter. While the cytoplasm is very flexible and the cytoskeleton can rearrange to fit through openings as narrow as 1 µm, the nuclear diameter (10–20 µm) and its considerable stiffness (2–10x stiffer than the cytoplasm) represent physical barriers to this process. “Thus, to enable metastasis, cancer cells must also increase their nuclear malleability.” Studies have shown that nuclear softening is associated with tumor aggressiveness and metastasis. Although nuclear softening is one of the ‘hallmarks of cancer' it remains poorly understood. Nuclear shape and stiffness are governed by a complex set of structural proteins that serve as both scaffolds and signaling proteins to influence almost all aspects of nuclear function. The best studied nucleostructural proteins are lamins, which are frequently downregulated in cancer. However, it is difficult to ascertain whether specific functional consequences are due to lamins or due to displacement of lamin-interacting proteins upon lamin loss. For example, nuclear size and shape is also governed by emerin, which binds to lamins at the nuclear envelope (NE) and upon lamin loss is retained in the endoplasmic reticulum. Like lamins, emerin is frequently mutated in cancer, with mutations in its transmembrane and actin-binding domains. “We found that in breast cancer, emerin expression in tumor tissue is significantly correlated to survival time [16]. These data suggest emerin plays a central role in pathogenic transformation and progression of malignant breast tissue.” DOI - https://doi.org/10.18632/oncotarget.28375 Correspondence to - James M. Holaska - holaska@rowan.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28375 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, emerin, metastasis, mechanotransduction, breast cancer, nucleoskeleton About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Ted Schaeffer is an internationally recognized urologist who specializes in prostate cancer. In this episode, Ted delves deep into the realm of prostate health, starting with strategies for vigilance and effective management of the issues that can arise with aging, including urinary symptoms, prostatitis, pelvic pain, and prostate inflammation. Ted sheds light on the popular drug finasteride, renowned for its dual purpose in prostate shrinkage and hair loss prevention, as well as the contentious topic of post-finasteride syndrome. Ted then shifts to the topic of cancer, explaining how androgens, genetics, and non-genetic factors contribute to the pathogenesis of prostate cancer. He provides valuable insights into cancer screening, examining blood-based screening tools like PSA and the use of MRI in facilitating biopsies and their interpretation. Finally, he explores the various treatment options for prostate cancer, including surgical interventions, androgen deprivation therapy, and more. We discuss: Changes to the prostate with age and problems that can develop [3:45]; Behavioral modifications to help manage nocturnal urinary frequency and other lower urinary tract symptoms [8:30]; Pharmacologic tools for treating nocturnal urinary frequency and lower urinary tract symptoms [16:30]; Surgical tools for treating symptoms of the lower urinary tract [26:15]; HoLEP surgery for reducing prostate size [32:30]; Prostate size: correlation with cancer and considerations for small prostates with persistent symptoms [40:30]; Prostatitis due to infection: symptoms, pathogenesis, and treatment [46:45]; Prostatitis caused by factors besides infection [58:45]; How to minimize risk of urosepsis in patients with Alzheimer's disease [1:05:00]; Prostate cancer: 5-alpha reductase inhibitors, how androgens factor into pathogenesis, and more [1:10:00]; Post-finasteride syndrome [1:18:15]; The relationship between testosterone and DHT and the development of prostate cancer over a man's lifetime [1:26:30]; How genetic analysis of a tumor can indicate the aggressiveness of cancer [1:35:15]; Pathogenesis and genetic risk factors of prostate cancer and the use of PSA to screen for cancer [1:37:45]; Non-genetic risk factors for prostate cancer [1:45:45]; Deep dive into PSA as a screening tool: what is PSA, definition of terms, and how to interpret results [1:56:30]; MRI as a secondary screening tool and the prostate biopsy options [2:13:15]; Ted's ongoing randomized trial comparing different methods of prostate biopsy [2:24:00]; Determining when a biopsy is necessary, interpreting results, explaining Gleason score, and more [2:27:00]; Implications of a Gleason score of 7 or higher [2:46:45]; Metastasis of prostate cancer to different body locations, treatment options, staging, and considerations for patients' quality of life and survival [2:53:30]; How prostate cancer surgery has improved [3:09:30];; Questions to ask your neurologist if you are considering prostatectomy for cancer [3:21:45]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
Why do I need two different medications for cancer pain? We explain their different roles and how using them as prescribed can improve your quality of life. In this Episode: 01:18 - Pumpkin Spice Muffins02:14 - Angel's Share and Devil's Cut05:26 - A Swan Song - History of the Phrase13:08 - Managing Breakthough Cancer Pain24:24 - Ask the Ethicist: "I'm Dying of Cancer. Do I have to Tell Anyone?" Follow us on Facebook | Instagram | Email us at mail@every1dies.orgClick on this link to Rate and Review our podcast!
A new editorial paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?” In their new editorial, researchers Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart, Sofia Braga, and Javier Cortés from Medica Scientia Innovation Research (MEDSIR) and Hospital Professor Doutor Fernando Fonseca discuss new drugs available for breast cancer (BC) patients with brain metastasis (BM). The better survival of Human Epidermal growth factor receptor-type 2 positive (HER2+) BC patients unmasked the biological predilection of this BC subtype for development of BM. Indeed, central nervous system (CNS) is a frequent metastatic site for HER2+ advanced BC patients. Over the last years, new therapeutic strategies targeting the HER2 protein have been introduced for systemic treatment of HER2+ BC - either tyrosine kinase inhibitors, monoclonal antibodies, or antibody-drug conjugates. Patients with BMs have a poorer outcome, compared with patients without BMs, but their prognosis is also improving with the introduction of new anti HER2+ - targeted therapies. “Our group has been working in the DEBBRAH trial, using trastuzumab deruxtecan for different settings of CNS involvement: stable or progressing BM and/or leptomeningeal carcinomatosis.” The team included patients with HER2+ and HER2-low BC. Activity of trastuzumab-deruxtecan in patients with HER2+ BC and untreated or progressing after local therapy BMs also has been shown in another phase II trial. “The final results are yet to be reported, but so far, we observed intracranial responses in HER2+ BC patients [7].” Read the full editorial: DOI: https://doi.org/10.18632/oncotarget.28435 Correspondence to: Marta Vaz Batista - marta.vaz@hff.min-saude.pt Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28435 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, brain metastasis, HER2+ breast cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
A new editorial paper was published in Oncotarget's Volume 14 on August 30, 2023, entitled, “Subpopulations of AIB1 isoform-expressing breast cancer cells enable invasion and metastasis.” In their new editorial, researchers Amber J. Kiliti, Ghada M. Sharif, Anton Wellstein, and Anna T. Riegel from Georgetown University Medical Center discuss potential mechanisms of breast cancer invasion and metastasis. Genetic and epigenetic events drive individual tumor cells to proliferate and expand into a heterogeneous mixture of cells that evade immune surveillance, acquire the ability to invade the vasculature and spread as metastatic seeds to distant sites. Organ metastasis contributes to more than 90% of all cancer-related deaths. “The model of Darwinian evolution explains the stepwise selection of cancer cells capable of invasion and metastatic spread and an extensive body of work supports that cancer cell-autonomous features match the selected cancer cell ‘seed' with the appropriate ‘soil' of the target organ.” However, this concept was challenged in a recent paper in Cancer Research. Sharif et al. observed that a subclonal population of cells in a heterogeneous tumor can significantly alter the growth characteristics, invasiveness and metastasis of an entire tumor through cell-cell crosstalk. These functionally relevant cell subpopulations are difficult to detect through bulk analysis though their presence may influence disease outcome and efficacy of treatments. “In their paper, Sharif et al. detailed how expression of a splice isoform of the transcriptional coregulator and oncogene Amplified In Breast Cancer 1 (AIB1) in a small subpopulation of cells can lead to increased tumor growth and invasion of surrounding tissues by ductal carcinoma in situ (DCIS) cells.” DOI - https://doi.org/10.18632/oncotarget.28452 Correspondence to - Anna T. Riegel - ariege01@georgetown.edu Video short - https://www.youtube.com/watch?v=_yZnwzitBek Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28452 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, AIB1, AIB1Δ4, breast cancer, invasion, metastasis About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
What do you do when frontline chemotherapy fails to stop cancer from growing? Your care team may offer the decision between aggressive anticancer treatment or palliative and hospice care. We share the story of one patient as she determined what was most important to her with the help of her multidisciplinary care team. Follow us on Facebook | Instagram | Email us at mail@every1dies.orgClick on this link to Rate and Review our podcast!
In this episode, we review the high-yield topic of Metastasis from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message
A new editorial paper was published in Oncotarget's Volume 14 on June 6, 2023, entitled, “A macrophage is a macrophage is a macrophage—in metastasis.” In this new editorial, researcher Thomas T. Tapmeier from Monash University, Hudson Institute of Medical Research and University of Oxford discusses a recent study he co-authored on how lung macrophages evolve during metastatic growth of lung colonies in a mouse model of melanoma. Macrophages have important roles in the response to infection or injury and can orchestrate the appropriate response after sampling their microenvironment, devouring anything untoward and presenting ingested antigens to T cells to elicit an adaptive immune response. In adult life, they develop from bone marrow-derived precursors and circulating monocytes, which differentiate into macrophages within tissue. “Apart from their role in clearing challenges to tissue integrity, macrophages have an essential role in growth-related processes such as angiogenesis and vascular remodelling, neural patterning, and ductal growth of developing glands [2].” However, their powers can be usurped by tumors, which cannot grow beyond a certain size or metastasis without the help of macrophages. This is crucial, as the primary tumor might be amenable to treatment—so that patients can live with it—but metastasis is yet untreatable and inevitably becomes incompatible with survival. Macrophages perform a range of physiological functions and are able to activate function-specific gene repertoires; however, surface markers for selectively targeting macrophages of one or another function are still elusive, despite recent advances in the field. “Thus, therapy attempts based on countering macrophages try to target the surface receptors that recruit them to sites of infection, inflammation or growth [5].” DOI - https://doi.org/10.18632/oncotarget.28423 Correspondence to - Thomas T. Tapmeier - thomas.tapmeier@monash.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28423 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, metastasis, macrophages, melanoma, CCR About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Today's poem is Dear Past and Future Metastasis, by Chiyuma Elliott. The Slowdown is your daily poetry ritual. In this episode, Major writes… “Today's fine poem makes delicate use of captured dialogue. The poem reveals our clumsy attempts to render legible who we are. Mostly we pass expected, typical speech between us but, occasionally, we make utterances so clear that they startle even ourselves.” Celebrate the power of poems with a gift to The Slowdown today. Every donation makes a difference: https://tinyurl.com/rjm4synp
What is the value of completion lymph node dissection for patients with melanoma with sentinel-node metastases? The Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1) confirmed that SLNB is an important part in the treatment of patients with melanoma, but what needed to be done beyond that in managing the axilla? Learning Objectives: In this episode, we review perioperative chemotherapy regimens for locally advanced, resectable Gastric cancer, standard of care, and the future role for immunotherapy. Hosts: Adam Yopp, MD, FACS (@AdamYopp) is an Associate Professor of Surgery at the UT Southwestern Medical Center and is Chief of the Division of Surgical Oncology. He also serves as Surgical Director of the Liver Tumor Program. Caitlin Hester, MD (@CaitlinAHester) is a new Assistant Professor of Surgery at the University of Miami Gilbert Murimwa, MD (@GilbertZMurimwa) is a PGY-4 General Surgery Resident at the UT Southwestern Medical Center and a research fellow in the Hamon Center for Therapeutic Oncology Research. Papers Referenced in this Episode: Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma Morton et al. https://www.nejm.org/doi/full/10.1056/nejmoa1310460 Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma Faries et al. https://www.nejm.org/doi/full/10.1056/nejmoa1613210 Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our Journal Review Series here: https://behindtheknife.org/podcast-series/journal-review/
© 2020-2025 Ivy Podcast Discovery LLC
